Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Active Systemic Lupus Erythematosus
View Full LandscapeTarget Indication
Active Systemic Lupus Erythematosus
Clinical Trial
NCT02794285Last updated: 2/14/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Saphnelo
Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
View on EMAHypercholesterolemia
Healthy Japanese Children Age 2 Years Through 6 Years
Generalized Anxiety Disorder
Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer